약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 1.

Table. 1.

Characteristics of the included studies

Author Article Type Title Protocol Patient Observation Period ITI Dose/Regimen Emicizumab Dosage Outcome Mesures
Batsuli G et al. (2019)8) Original Article Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis Atlanta protocol 7 4M 50-100 IU/kg, 3 times per week. starting 4 weeks after initiation of emicizumab. Loading dose: 3 mg/kg weekly × 4 week, Maintenance dose: 1.5 mg/kg weekly or 3 mg/kg every 2 week Inhibitor titer
Carcao M et al. (2019)9) Original Article The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab FIT protocol - - Start with 50 IU/kg, 3 times per week. If inhibitor titire rises, 200 IU/kg daily. If non-responding after 9 months, product swith and/or start emicizumab. - Inhibitor titer
Nagao A et al. (2019)10) Abstract-case study Immune Tolerance Induction Using Low-dose Fc Fusion Recombinant Factor VIII on Emicizumab in Hemophilia A Patients with Inhibitors, Tokyo Protocol Tokyo protocol 3 - low- dose (less than 50 IU/kg) extended half-life FVIII 2 times per week. - Dose of FVIII and dosing schedule
Wieland I et al. (2019)11) Abstract-case study Case report: Inhibitor Improvement with Low Dose Immune Tolerance Induction (ITI) with rFVIIIFc and Emicizumab after Failed First Line Therapy with High Dose ITI Atlanta protocol 1 4Y 100 IU/kg, 3 times per week. starting 4 weeks after initiation of emicizumab. Loading dose: 3 mg/kg weekly × 4 week, Maintenance dose: 1.5 mg/kg weekly or 3 mg/kg every 2 week Inhibitor titer and immunological parameters
Batsuli G et al. (2020)12) Abstract-case study Updates on the atlanta protocol cohort: Two-year institutional outcomes on immune tolerance induction in children with hemophilia A and inhibitors on emicizumab Atlanta protocol 7 2Y 50-100 IU/kg, 3 times per week. starting 4 weeks after initiation of emicizumab. Loading dose: 3 mg/kg weekly × 4 week, Maintenance dose: 1.5 mg/kg weekly or 3 mg/kg every 2 week Inhibitor titer
Camelo RM et al. (2021)13) Abstract-case study Cost-effectiveness analysis of the brazilian immune tolerance induction protocol with recombinant factor VIII and prophylaxis with bypassing agents or emicizumab BIP protocol - - 50 IU/kg X 3 times per week. upon poor response, increase to 100 IU/kg per day Loading dose: 3 mg/kg weekly × 4 week, Maintenance dose: 1.5 mg/kg weekly Ccost-effectiveness analysis
Chuansumrit A et al. (2021)14) Abstract-case study Effectiveness of monthly low-dose emicizumab prophylaxis without 4-week loading doses among patients with hemophilia a with and without inhibitor: A case series report - 1 1Y 100 units/kg of extended half-life factor VIII concentrate 3 times weekly. whole vial of emicizumab at 30, 75, 105 mg monthly except 3 patients receiving 60 mg monthly which was equal to 1.1 to 1.6 mg/kg of emicizumab Bleeding rate
Garcia J et al. (2021)15) Brief Report Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab - 1 - 200 units/kg, daily Loading dose: 3 mg/kg weekly × 4 week, Maintenance dose: 1.5 mg/kg weekly Bleeding rate
Escuriola-Ettingshausen C et al. (2021)16) Original Article Design of an international investigatorinitiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE) MOTIVATE protocol (120) (5Y) Nuwiq® or octanate® or wilate® - Inhibitor titer
Matsushita T et al. (2022)17) Original Article AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors AKASUSKI protocol (20) (193W) 50 IU/kg, 3 times per week for plasma-derived FVIII. or 2 times per week for recombinant FVIII Loading dose: 3 mg/kg weekly × 4 week, Maintenance dose: 1.5 mg/kg weekly or 3 mg/kg every 2 week or 6 mg/kg every 4 week Bleeding rate

f/u date, follow up date; ITI, immune tolerance induction; M, month; Y, year; FIT, future of immunotolerance treatment; BU, bethesda unit; BIP, brazilian ITI protocol

( ): indicates virtual study design

Yakhak Hoeji 2023;67:75-84 https://doi.org/10.17480/psk.2023.67.2.75
© 2023 Yakhak Hoeji